Combination immunotherapy of oncolytic flu-vectored virus and PD-1 blockade enhances antitumor activity in hepatocellular carcinoma

Hongyu Yu,Fang Sun,Yan Xu,Hao Yang,Chongyu Tian,Cong Li,Yimin Kang,Lei Hao,Penghui Yang,Fang SUN,Yan XU,Lei HAO

DOI: https://doi.org/10.1089/hum.2023.150

2024-02-23

Human Gene Therapy

Abstract:Background: Oncolytic viruses (OVs) have emerged as promising agents for antitumor therapy; however, their effectiveness remains limited. Our objective in this study was to enhance the antitumor efficacy of OVs by combining them with immune checkpoint inhibitors (ICIs). Methods: Using reverse genetics technology, we developed a novel oncolytic influenza virus called delNS1-GM-CSF. Characterization of delNS1-GM-CSF included hemagglutination and TCID50 assays, followed by purification and observation of viral morphology using electron microscopy. The expression of GM-CSF in delNS1-GM-CSF was quantified by RT-qPCR, and the GM-CSF protein level was measured by ELISA after infection. The tumor-killing effect of delNS1-GM-CSF was evaluated using a mouse model of hepatocellular carcinoma (HCC). Transcriptome sequencing of mouse tumor tissue was conducted to investigate signal transduction pathways, and validation was performed through Western blotting. T-cell infiltration into HCC tumors post-treatment was analyzed using flow cytometry and immunohistochemistry. Results: DelNS1-GM-CSF exhibited typical characteristics of an influenza virus, demonstrating a hemagglutination titer of 28-29. Importantly, delNS1-GM-CSF selectively targeted and eliminated HCC cells without harming normal hepatocytes. Combination therapy with delNS1-GM-CSF and PD-1 blockade significantly enhanced antitumor effects and substantially improved mouse survival. Moreover, we identified the involvement of the JAK2-STAT3 pathway in the antitumor impact of the combination therapy, leading to activation of CD4+ and CD8+ T cells. Notably, the combined therapy also showed promising efficacy against distant tumors. Conclusion: DelNS1-GM-CSF displayed potent oncolytic activity against HCC and stimulated intra-tumor T-cell infiltration through activation of the JAK2-STAT3 pathway. Combination therapy with delNS1-GM-CSF and PD-1 blockade represents a promising immunotherapeutic strategy for HCC.

genetics & heredity,medicine, research & experimental,biotechnology & applied microbiology